Tamtam Try Tamtam free
Recordati logo

Recordati account plan

Developing and commercializing medicines

At a glance

Recordati is a Milan-based pharmaceutical group in rare diseases and specialty and primary care, with EUR 2,618.4 million of FY 2025 revenue.

Recordati is a Milan-headquartered pharmaceutical group that combines a Specialty & Primary Care business (urology, cardiovascular, gastro-intestinal, cough and cold, consumer brands) with a global Rare Diseases business in endocrinology, hema-oncology and metabolic disorders. It is present in around 150 countries and had 4,693 employees at year-end 2025. FY 2025 net revenue was EUR 2,618.4 million (+11.8%), EBITDA EUR 991.1 million (37.8% margin) and net income EUR 443.6 million. A tender offer by CVC Fund IX and GBL closed on 9 November 2026 with about 91.451% of the capital, and a squeeze-out and delisting from Euronext Milan were expected by the end of November 2026; the company is now under the management and coordination of Respighi TopCo S.à r.l.

Business units

Strategic priorities

2025-2027 Three-Year Plan targets
The plan approved in April 2025 targets FY 2027 net revenue of EUR 3,000-3,200 million, EBITDA of EUR 1,140-1,225 million and adjusted net income of EUR 770-820 million, excluding any US tariff or most-favoured-nation pricing impact.
Isturisa growth in the US
After the April 2025 US label expansion to Cushing's syndrome, Isturisa peak year sales are estimated above EUR 1.2 billion. The US field force and MSL team were expanded to reach non-overt patients, who were around 20% of the treated population in Q1 2026.
Bolt-on business development and M&A
Capital allocation combines a progressive dividend with bolt-on M&A and licensing; 2025-2026 deals brought in Vazkepa (Amarin), Inrebic for Japan, mRNA-3927 (Moderna) and zilganersen (Ionis).
Rare disease pipeline and lifecycle management
Pasireotide in post-bariatric hypoglycaemia met its Phase 2 endpoint, sutimlimab enters a pivotal Phase 3 in chronic ITP at the beginning of 2027, and an Isturisa Phase IV began in August 2026. The group says it will not do discovery or very high-risk R&D.
One company culture and digitalisation
Organisational priorities include simplification, digitalisation and harmonised ways of working, new IT systems for the digitalisation roadmap, and increasing use of AI in real-world evidence and clinical development.

Latest results

In the first nine months of 2026 net revenue was EUR 2,103.7 million, up 7.5% (+9.4% like-for-like at constant exchange rates), and EBITDA EUR 801.1 million at a 38.1% margin. Rare Diseases grew 18.7% to EUR 928.2 million, led by Isturisa (EUR 285.9 million, +54.8%) and Enjaymo (EUR 135.2 million, +30.0%), while Specialty & Primary Care was EUR 1,135.5 million (+0.5%). Free cash flow was EUR 459.8 million and net debt fell to EUR 1,697.8 million, around 1.6x EBITDA. FY 2026 guidance (revenue EUR 2,730-2,800 million, EBITDA EUR 995-1,030 million) was confirmed, with the group expecting the upper end of the ranges.

Investments and deals

mRNA-3927 licence from Moderna
Licensed on 29 January 2026 for propionic acidemia, with a US$ 50 million upfront and up to US$ 110 million in near-term milestones; data readout expected by end-2026.
Vazkepa licence from Amarin
Licensed in June 2025 for 59 countries focused on Europe (upfront US$ 25 million); expected to exceed EUR 40 million in revenues in 2027.
Inrebic and zilganersen licences
Inrebic was in-licensed for Japan (upfront US$ 11 million), with launch expected mid-2026; zilganersen for Alexander disease was licensed from Ionis outside the US on 25 June 2026.
Isturisa commercial investment
An extra EUR 40-50 million of Isturisa investment in 2026, reaching full speed in the second half, funds the expanded US customer-facing teams.
Manufacturing footprint changes
Pardubice ceased production on 31 December 2025; Campoverde is undergoing an industrial transformation including a photovoltaic plant of approximately 10 MWp.

Challenges and risks

Currency headwinds
Adverse FX cost EUR 64.2 million in FY 2025, mainly the Turkish lira and the US dollar, and FY 2026 guidance assumes an FX headwind of about -3.5%.
Pricing and access pressure
Isturisa was refused national reimbursement in China, leading to the liquidation of the Chinese rare diseases subsidiary, and Türkiye approved no price increase in 2025.
Flat Specialty & Primary Care
SPC was flat in 2026 on the loss of the Cardicor licence in Italy and weaker cough and cold seasons; Italy fell 8.5% and Germany 6.6% in H1 2026.
US tariff and pricing exposure
Targets exclude US tariffs and most-favoured-nation pricing; US inventory was built ahead of potential tariffs to cover the majority of 2026 sales.
Supply chain and geopolitical risk
The risk catalogue names geopolitical exposure (Russia, Türkiye, sanctions), manufacturing and supply-chain disruption across over 150 contract manufacturers, and cyber risk.

What leadership says

“Our Rare Diseases franchise remains a key driver of growth, supported by strong momentum across our portfolio, particularly Isturisa® in the U.S., and continued progress in advancing our pipeline.”

Rob Koremans, Chief Executive Officer · First Nine Months 2026 Results press release, 2026-11-10

“we will not start to do discovery or very high-risk R&D”

Rob Koremans, Chief Executive Officer · Full Year 2025 Results Conference Call, 2026-02-18

“the market split is still heavily weighted towards the overt population”

Scott Pescatore, Executive VP Rare Diseases · Full Year 2025 Results Conference Call, 2026-02-18

“provide a solid foundation for sustainable and continued growth”

Andrea Recordati, Chairman · Annual Report 2025, on the Board and the Three-Year Plan

Where a supplier can help

US rare disease patient finding
The push to reach non-overt Cushing's syndrome patients with an expanded US field force and MSL team creates demand for diagnosis education, HCP targeting and patient services support.
Integration of licensed assets
Frequent bolt-on licensing (Moderna, Ionis, Amarin) means repeated launch and integration work where regulatory, market access and commercial launch partners can help.
Digitalisation roadmap
New IT systems, harmonised ways of working and AI in real-world evidence and clinical development point to openings for software, data and implementation suppliers.
Supply-chain resilience
Reliance on over 150 contract manufacturers, tariff-driven inventory build and the Campoverde transformation give room for supply planning, logistics and plant engineering offers.
SPC cost efficiency
With SPC flat and the commercial organisation right-sized, suppliers that improve commercial productivity or operating cost in European primary care fit the margin focus.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Recordati?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Recordati

What does Recordati do?

Recordati is a Milan-based pharmaceutical group that sells specialty and primary care brands across Europe, Russia/CIS, Türkiye and North Africa, and rare disease treatments worldwide, including Isturisa and Enjaymo.

What is Recordati's revenue?

FY 2025 net revenue was EUR 2,618.4 million, up 11.8%, with EBITDA of EUR 991.1 million. For the first nine months of 2026 revenue was EUR 2,103.7 million, and FY 2026 guidance is EUR 2,730-2,800 million.

How many employees does Recordati have?

Recordati had 4,693 employees at year-end 2025 and is present in around 150 countries.

Who owns Recordati?

A tender offer by CVC Fund IX and GBL closed on 9 November 2026 with about 91.451% of the capital at EUR 53 per share; a squeeze-out and delisting from Euronext Milan were expected by the end of November 2026.

Who leads Recordati?

Rob Koremans is CEO, Andrea Recordati is Chairman and Mike McClellan has been Group CFO since 1 January 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)